Vontobel Holding Ltd. Has $173.05 Million Stock Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Vontobel Holding Ltd. raised its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 90.1% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 418,563 shares of the company's stock after buying an additional 198,404 shares during the period. Vontobel Holding Ltd. owned about 0.51% of IDEXX Laboratories worth $173,051,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Asset Management One Co. Ltd. increased its holdings in shares of IDEXX Laboratories by 6.1% in the fourth quarter. Asset Management One Co. Ltd. now owns 52,844 shares of the company's stock valued at $21,927,000 after purchasing an additional 3,057 shares in the last quarter. Avestar Capital LLC grew its holdings in IDEXX Laboratories by 5.9% during the 4th quarter. Avestar Capital LLC now owns 804 shares of the company's stock worth $332,000 after acquiring an additional 45 shares during the period. Howard Bailey Securities LLC grew its holdings in IDEXX Laboratories by 22.1% during the 4th quarter. Howard Bailey Securities LLC now owns 1,094 shares of the company's stock worth $452,000 after acquiring an additional 198 shares during the period. Fiera Capital Corp grew its holdings in IDEXX Laboratories by 12.3% during the 4th quarter. Fiera Capital Corp now owns 141,198 shares of the company's stock worth $58,377,000 after acquiring an additional 15,463 shares during the period. Finally, Marks Group Wealth Management Inc grew its holdings in IDEXX Laboratories by 8.6% during the 4th quarter. Marks Group Wealth Management Inc now owns 11,009 shares of the company's stock worth $4,552,000 after acquiring an additional 869 shares during the period. Institutional investors and hedge funds own 87.84% of the company's stock.

IDEXX Laboratories Stock Up 1.0 %

IDXX traded up $4.53 during trading on Tuesday, hitting $449.06. The company had a trading volume of 632,107 shares, compared to its average volume of 711,523. The company has a market capitalization of $36.77 billion, a PE ratio of 42.09, a PEG ratio of 3.47 and a beta of 1.37. IDEXX Laboratories, Inc. has a one year low of $398.50 and a one year high of $583.39. The firm's 50-day moving average price is $430.82 and its 200 day moving average price is $452.56. The company has a quick ratio of 1.03, a current ratio of 1.31 and a debt-to-equity ratio of 0.28.

Insider Activity at IDEXX Laboratories

In other IDEXX Laboratories news, EVP George Fennell sold 9,986 shares of IDEXX Laboratories stock in a transaction on Monday, February 10th. The shares were sold at an average price of $462.53, for a total value of $4,618,824.58. Following the sale, the executive vice president now directly owns 8,176 shares in the company, valued at approximately $3,781,645.28. The trade was a 54.98 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Sophie V. Vandebroek sold 344 shares of IDEXX Laboratories stock in a transaction on Wednesday, November 27th. The shares were sold at an average price of $420.44, for a total transaction of $144,631.36. Following the completion of the sale, the director now owns 905 shares in the company, valued at $380,498.20. The trade was a 27.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 13,330 shares of company stock valued at $6,161,276. 2.11% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of analysts have commented on IDXX shares. Piper Sandler lifted their target price on shares of IDEXX Laboratories from $435.00 to $510.00 and gave the stock a "neutral" rating in a report on Monday, February 10th. StockNews.com lowered shares of IDEXX Laboratories from a "buy" rating to a "hold" rating in a report on Wednesday, February 5th. Leerink Partners started coverage on shares of IDEXX Laboratories in a report on Monday, December 2nd. They set an "outperform" rating and a $500.00 target price for the company. Barclays lifted their target price on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the stock an "overweight" rating in a report on Tuesday, February 4th. Finally, Morgan Stanley reduced their price target on shares of IDEXX Laboratories from $559.00 to $550.00 and set an "overweight" rating on the stock in a research report on Wednesday, January 29th. Four research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, IDEXX Laboratories has a consensus rating of "Moderate Buy" and a consensus price target of $533.75.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.